Drug Profile
OligoG
Alternative Names: Alginate oligosaccharide (G-block) fragment; Oligo-COPD-10/20(1); OligoG CF-5/20; OligoG-COPD-5/20; Oligosaccharide nanotherapeutic - AlgiPharmaLatest Information Update: 23 Jul 2022
Price :
$50
*
At a glance
- Originator Norwegian university of science and technology
- Developer AlgiPharma
- Class Antibacterials; Antibronchitics; Antifibrotics; Antifungals; Bronchodilators; Oligosaccharides
- Mechanism of Action Bacterial growth inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cystic fibrosis
- No development reported Bacterial infections; Chronic obstructive pulmonary disease; Mycoses
Most Recent Events
- 23 Jul 2022 No development reported - Phase-II for Cystic fibrosis in Australia (Inhalation)
- 27 Jun 2022 AlgiPharma AS withdraws prior to enrolment a phase II/III clinical trials in Cystic fibrosis (In children, In adults, In the elderly) in Germany due to not feasible (Inhalation) (NCT03698448) (EudraCT2018-000378-30)
- 15 May 2019 Phase-II clinical trials in Cystic fibrosis in Australia (Inhalation) (NCT03822455)